The significant upward revision in Medistim's price target is driven by higher consensus revenue growth forecasts and a rising future P/E multiple, resulting in the fair value increasing to NOK290.00.
Valuation Changes
Summary of Valuation Changes for Medistim
- The Consensus Analyst Price Target has significantly risen from NOK255.00 to NOK290.00.
- The Consensus Revenue Growth forecasts for Medistim has significantly risen from 7.6% per annum to 8.9% per annum.
- The Future P/E for Medistim has risen from 32.78x to 35.15x.
Have other thoughts on Medistim?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.